Loading
Life sciences · Phase 2 Trial
ClinicalTrials.gov · November 3, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 2 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07914309). This is a study registration, not published results. Lead sponsor: Washington University School of Medicine. Recruitment status: NOT_YET_RECRUITING. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 17 participants (ESTIMATED). Conditions: Triple Negative Breast Cancer, Triple Negative Breast Cancer (TNBC), Breast Cancer. Interventions: DRUG: Dexamethasone; DRUG: Famotidine; DRUG: Diphenhydramine; DRUG: Olanzapine; DRUG: Paclitaxel; DRUG: Carboplatin; BIOLOGICAL: Pembrolizumab; DRUG: Doxorubicin; DRUG: Cyclophosphamide. Primary outcome measures: Incidence of hypersensitivity reactions (HSRs) requiring reintroduction of dexamethasone , During the 10 dexamethasone-free weekly paclitaxel/carboplatin containing infusions (total estimated time: 10 weeks). Brief summary: This is a single-arm, open-label, phase II trial designed to prospectively evaluate the safety and feasibility of dexamethasone de-escalation in patients undergoing standard neoadjuvant chemotherapy and immunotherapy for triple negative breast cancer.